about
Potential Gene Interactions in the Cell Cycles of Gametes, Zygotes, Embryonic Stem Cells and the Development of CancerClinical potential of pacritinib in the treatment of myelofibrosisBiosensors in clinical practice: focus on oncohematology.Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibitionNovel therapies for myelofibrosisMicroarray and Proteomic Analyses of Myeloproliferative Neoplasms with a Highlight on the mTOR Signaling PathwayPseudokinases: update on their functions and evaluation as new drug targets.Efficacy and safety of JAK inhibitor INC424 in patients with primary and post-polycythemia vera or post-essential thrombocythemia myelofibrosis in the Chinese population.The Thrombopoietin Receptor: Structural Basis of Traffic and Activation by Ligand, Mutations, Agonists, and Mutated Calreticulin.Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells.c-Abl activates janus kinase 2 in normal hematopoietic cells.Take (STAT)5: jazzing up T-cell leukemiaTherapy targets in glioblastoma and cancer stem cells: lessons from haematopoietic neoplasms.Intersection of mTOR and STAT signaling in immunityFunctional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3-mutation-positive leukemia.Comprehensive analysis of transcriptome variation uncovers known and novel driver events in T-cell acute lymphoblastic leukemiaEmerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignanciesThe synthetic tryptanthrin analogue suppresses STAT3 signaling and induces caspase dependent apoptosis via ERK up regulation in human leukemia HL-60 cells.ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activationMutational spectrum of adult T-ALLThe ITIM-containing receptor LAIR1 is essential for acute myeloid leukaemia developmentDuring Drosophila disc regeneration, JAK/STAT coordinates cell proliferation with Dilp8-mediated developmental delay.Molecular insights into regulation of JAK2 in myeloproliferative neoplasmsApontic regulates somatic stem cell numbers in Drosophila testesEffect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosisDeletion of Stat3 enhances myeloid cell expansion and increases the severity of myeloproliferative neoplasms in Jak2V617F knock-in mice.Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemiaAbnormal repression of SHP-1, SHP-2 and SOCS-1 transcription sustains the activation of the JAK/STAT3 pathway and the progression of the disease in multiple myeloma.Contribution of JAK2 mutations to T-cell lymphoblastic lymphoma development.Association of cyclin D and estrogen receptor α36 with hepatocellular adenomas of female mice under chronic endoplasmic reticulum stress.Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma.Cross-platform assessment of genomic imbalance confirms the clinical relevance of genomic complexity and reveals loci with potential pathogenic roles in diffuse large B-cell lymphoma.Antitumor activity of 7RH, a discoidin domain receptor 1 inhibitor, alone or in combination with dasatinib exhibits antitumor effects in nasopharyngeal carcinoma cells.Lnk adaptor suppresses radiation resistance and radiation-induced B-cell malignancies by inhibiting IL-11 signaling.Antagonizing STAT5B dimerization with an osmium complex.Drosophila as a model to study the role of blood cells in inflammation, innate immunity and cancer.Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes.Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma.JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.Tumor necrosis factor-alpha-converting enzyme activities and tumor-associated macrophages in breast cancer.
P2860
Q26781101-47DB2452-8D8F-48C9-88EE-D415F43E44FCQ26796450-BDA55E44-F9FC-4F87-8086-83ACECCAB8CCQ27027114-D6A37FB1-97A0-4679-BCD4-96EB78D39B26Q27683852-46DA0203-2579-4F24-A009-7C8A0BB2D1FEQ28081693-EB21DBB7-82E8-4EDD-853D-011025F7638DQ28547283-9A85B3A5-064F-4C69-B50D-A9E7404B1F19Q30397636-33081AC5-FD1D-4C4E-A187-C5EE9CA25098Q33436870-E20B252B-EB37-46AE-A090-7BB20704FFC2Q33440994-5EBB7BFE-0106-43AC-A341-13791DD848F1Q33576089-37D6BD12-BC00-4719-BD90-3523C1E95F68Q33985308-53A344F7-7AD5-4ADC-9918-3B0C798D8571Q34106785-DC2EC359-FA3F-49A5-88B1-57B5317E7055Q34154786-5F80C96B-BE06-4E81-967D-B159314C2DB1Q34978661-105918C7-26CA-4698-A115-40A6969E818BQ35072638-8C5603CA-274E-472D-AE6F-63D65A5562C8Q35075158-5A68C297-9ACB-4389-92AB-FB5E3EACE4DAQ35132241-81CA24E5-D7EE-4DD3-AB74-02A12FE5C98FQ35406528-6B1457EA-987D-4135-94C6-DA6898C41747Q35484880-44DF0348-B306-40CD-B1B7-E28E966963B1Q35550090-31991CEF-AB93-4519-A73F-0A30FEF1BBA5Q35561510-A525D083-3B9F-4524-BC15-C827B7C0292EQ35590235-C8E1978D-9491-4305-B06A-47B0D0FD9602Q35661987-482E5C78-BC8A-4900-BFA8-8DF0ECD76A55Q35963326-31D59EA7-A64D-4FC0-89BF-ED264A8CB811Q36050183-485D6F88-06C1-4C47-B074-C28459BF6D38Q36137458-CDAA6FDE-560A-405F-BE9A-BEF1351551CCQ36155080-914BCD30-69B7-4E7A-8E3E-7228795F74FCQ36331908-3B69E049-10B3-4C78-A25B-51BC75FBB2CCQ36442514-8DE66234-5837-4E70-A464-D16EED0FF7AEQ36644420-F3F46411-145A-4A48-9998-7C1BBC0AE7B5Q36905691-BFBDC4B7-70F5-4884-8AE3-6F0400799C53Q37132882-5E3DCDC9-3B05-41A1-A81E-108B90933D40Q37407102-B8106E09-110D-4D6D-966C-0C2D63C478D5Q37409325-3106DE55-C7CB-4848-AE1F-4057220A6C32Q37419916-C7C3EA62-B247-411C-8D46-ED13F55300AFQ37453657-165FDD4D-1460-4A26-9325-C48FE76DB6D7Q37548944-1CBC1EBD-D6C7-44D8-BE5C-0E428BC2C156Q37558207-79F4E9D2-E7F7-49A2-97C4-A2FFCB694962Q37623539-040E1549-0628-4693-B16D-6830196E3247Q38144933-34445053-FE3D-4AA7-B177-1B635C16342A
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
JAK/STAT signaling in hematological malignancies.
@ast
JAK/STAT signaling in hematological malignancies.
@en
JAK/STAT signaling in hematological malignancies.
@nl
type
label
JAK/STAT signaling in hematological malignancies.
@ast
JAK/STAT signaling in hematological malignancies.
@en
JAK/STAT signaling in hematological malignancies.
@nl
prefLabel
JAK/STAT signaling in hematological malignancies.
@ast
JAK/STAT signaling in hematological malignancies.
@en
JAK/STAT signaling in hematological malignancies.
@nl
P356
P1433
P1476
JAK/STAT signaling in hematological malignancies
@en
P2093
S N Constantinescu
W Vainchenker
P2888
P304
P356
10.1038/ONC.2012.347
P407
P577
2012-08-06T00:00:00Z
P6179
1038314954